NON-HORMONAL TREATMENT

Elinzanetant (Lynkuet)

Elinzanetant received FDA approval as a non-hormonal treatment for vasomotor symptoms of menopause, particularly hot flashes and night sweats.

*Content reviewed by HotPause Health Medical Advisor & Doctor of Pharmacy Audrey Hou, PharmD, CMPP

The U.S. Food and Drug Administration (FDA) has approved Lynkuet (elinzanetant) for the treatment of moderate to severe vasomotor symptoms (VMS) commonly known as hot flashes and night sweats associated with menopause.

This approval marks a significant milestone for women seeking non-hormonal relief from the most common and disruptive symptoms of menopause, expanding options beyond estrogen-based therapies.

How Lynkuet Works

Lynkuet is the first dual neurokinin-1 (NK1) and neurokinin-3 (NK3) receptor antagonist approved for menopause-related vasomotor symptoms.
When estrogen levels fall during menopause, certain neurons in the hypothalamus (called KNDy neurons) become overactive, sending false “overheating” signals that trigger hot flashes and night sweats.
By blocking NK1 and NK3 receptors, Lynkuet helps calm this overactivity, restoring balance to the body’s internal thermostat—without using hormones.
Typical Administration: 120 mg (two 60 mg capsules) taken once daily at bedtime. Can be taken with or without food, both are fine; consistency matters most. Because some people experience drowsiness or dizziness, bedtime dosing is recommended.

Who Should Consider Lynkuet

Lynkuet may be an appropriate option for women who:

• Are experiencing moderate to severe hot flashes or night sweats that disrupt sleep, work, or daily life
• Prefer to avoid hormone therapy, or have medical reasons not to use estrogen (such as certain cancer histories or cardiovascular risks)
• Are willing to complete baseline and follow-up liver tests as part of monitoring
• Are not pregnant or breastfeeding, and use effective contraception if of reproductive potential

Women already taking medications that strongly affect CYP3A4 metabolism (including some antifungals, antibiotics, anticonvulsants, or grapefruit products) should discuss possible interactions with their prescriber before starting Lynkuet.

Potential Benefits of Lynkuet for Menopause

Clinical trials show that Lynkuet offers meaningful benefits for women struggling with hot flashes and night sweats:

• Reduction in Frequency and Severity: Women experienced statistically significant decreases in both the number and intensity of hot flashes by week 4, with sustained improvement through week 12 and beyond.
• Better Sleep: Participants reported improved sleep quality as nighttime symptoms eased.
• Improved Quality of Life: Many women noted reductions in daily discomfort, fatigue, and mood disruption related to temperature swings.
• Non-Hormonal Relief: Offers an option for those unable or unwilling to use estrogen.

Usage and Considerations

• When to Take: Once daily at bedtime
• Monitoring: Liver function tests should be performed before starting and again at 3 months
• Drug Interactions: Avoid strong or moderate CYP3A4 inhibitors or inducers, as well as grapefruit
• Alcohol: Best minimized, as it may enhance drowsiness
• Lynkuet is not indicated for mild or occasional hot flashes, nor is it a substitute for hormone therapy in women who can safely take estrogen and prefer it.

Side Effects and Considerations

Common Side Effects:

• Headache
• Fatigue or sleepiness
• Dizziness
• Nausea or reflux

Less Common but Important:

• Mild increases in liver enzymes (hence the lab monitoring)
• Rarely, photosensitivity or lightheadedness
• Avoid use during pregnancy, as studies in animals suggest risk of pregnancy loss

Women with a history of seizures should discuss risks carefully with their healthcare provider, as isolated cases of seizure were reported in clinical trials.

Conclusion

Lynkuet represents an important advancement in non-hormonal menopause care, providing effective relief for hot flashes and night sweats through a novel, brain-targeted mechanism.
As with any medication, talk with your clinician to determine whether Lynkuet is right for you, especially if you take other medications or have liver, neurological, or cardiovascular conditions.
This new therapy gives women more choice, more control, and renewed comfort as they move through menopause with confidence.

Reference:

1. Lynkuet [package insert]. Whippany, NJ: Bayer U.S. LLC; 2025.
2. Bayer. FDA Approves Lynkuet (elinzanetant) for Moderate to Severe Vasomotor Symptoms Associated with Menopause. October 2025.

The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.